Arcus Biosciences (RCUS) Revenue & Revenue Breakdown
Arcus Biosciences Revenue Highlights
Latest Revenue (Y)
$117.00M
Latest Revenue (Q)
$48.00M
Main Segment (Y)
Other Collaboration Revenue
Arcus Biosciences Revenue by Period
Arcus Biosciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $117.00M | 4.46% |
| 2022-12-31 | $112.00M | -70.75% |
| 2021-12-31 | $382.88M | 393.93% |
| 2020-12-31 | $77.52M | 416.78% |
| 2019-12-31 | $15.00M | 79.58% |
| 2018-12-31 | $8.35M | 491.15% |
| 2017-12-31 | $1.41M | 100.00% |
| 2016-12-31 | - | - |
Arcus Biosciences generated $117.00M in revenue during NA 2023, up 4.46% compared to the previous quarter, and up 1400.69% compared to the same period a year ago.
Arcus Biosciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $48.00M | 23.08% |
| 2024-06-30 | $39.00M | -73.10% |
| 2024-03-31 | $145.00M | 367.74% |
| 2023-12-31 | $31.00M | -3.13% |
| 2023-09-30 | $32.00M | 10.34% |
| 2023-06-30 | $29.00M | 16.00% |
| 2023-03-31 | $25.00M | 7146.38% |
| 2022-12-31 | $345.00K | -98.97% |
| 2022-09-30 | $33.58M | 25.49% |
| 2022-06-30 | $26.76M | 48.62% |
| 2022-03-31 | $18.00M | -94.92% |
| 2021-12-31 | $354.50M | 3646.95% |
| 2021-09-30 | $9.46M | - |
| 2021-06-30 | $9.46M | - |
| 2021-03-31 | $9.46M | -0.27% |
| 2020-12-31 | $9.49M | -85.30% |
| 2020-09-30 | $64.53M | 3587.43% |
| 2020-06-30 | $1.75M | - |
| 2020-03-31 | $1.75M | -82.05% |
| 2019-12-31 | $9.75M | 457.14% |
| 2019-09-30 | $1.75M | - |
| 2019-06-30 | $1.75M | - |
| 2019-03-31 | $1.75M | 12.04% |
| 2018-12-31 | $1.56M | -63.60% |
| 2018-09-30 | $4.29M | 243.28% |
| 2018-06-30 | $1.25M | - |
| 2018-03-31 | $1.25M | - |
| 2017-12-31 | $1.25M | 666.87% |
| 2017-09-30 | $163.00K | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | - |
Arcus Biosciences generated $48.00M in revenue during Q3 2024, up 23.08% compared to the previous quarter, and up 165.52% compared to the same period a year ago.
Arcus Biosciences Revenue Breakdown
Arcus Biosciences Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| Other Collaboration Revenue | $37.00M | $33.00M | - | - |
| License and Development Services Revenue | - | $74.00M | - | - |
| Taiho Access Rights | - | - | $7.00M | - |
| Taiho License to Domvanalimab | - | - | $15.00M | - |
| Gilead License to Domvanalimab | - | - | $328.84M | - |
| Gilead Access Rights | - | - | $30.91M | $15.42M |
| Development Services for all Gilead Programs | - | - | $1.14M | - |
| Taiho Collaboration Agreement | - | - | - | $7.00M |
| Gilead License To Zimberelimab | - | - | - | $55.10M |
Latest
Arcus Biosciences's latest annual revenue breakdown by segment (product or service), as of Dec 23: Other Collaboration Revenue (100.00%).
Quarterly Revenue by Product
| Product/Service | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other Collaboration Revenue | $7.00M | $10.00M | $9.00M | $10.00M | $10.00M | $8.00M | $8.05M | - | - | - | - | - | - | - | - | - |
| License and Development Services Revenue | $41.00M | $135.00M | $22.00M | $19.00M | $17.00M | $25.63M | - | - | - | - | - | - | - | - | - | - |
| License and Development Services for All Gilead Programs | - | - | - | - | - | - | - | $23.74M | $16.69M | $7.94M | - | - | - | - | - | - |
| Gilead Access Rights | - | - | - | - | - | - | - | $8.32M | $8.32M | $8.32M | $7.78M | $7.71M | $7.71M | $7.74M | $7.68M | - |
| Taiho Access Rights | - | - | - | - | - | - | - | $1.52M | $1.75M | $1.75M | - | - | - | - | - | - |
| Collaboration | - | - | - | - | - | - | - | - | - | - | - | $7.71M | - | - | - | - |
| License | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Taiho Collaboration Agreement | - | - | - | - | - | - | - | - | - | - | - | - | $1.75M | $1.75M | $1.75M | $1.75M |
| Gilead License To Zimberelimab | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $55.10M |
Latest
Arcus Biosciences's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: License and Development Services Revenue (85.42%), and Other Collaboration Revenue (14.58%).
Arcus Biosciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PTCT | PTC Therapeutics | $937.82M | $135.42M |
| APLS | Apellis Pharmaceuticals | $366.28M | $176.57M |
| BPMC | Blueprint Medicines | $249.38M | $128.18M |
| RCUS | Arcus Biosciences | $117.00M | $48.00M |
| KRYS | Krystal Biotech | $50.70M | $83.84M |
| VECT | VectivBio | $27.34M | $676.00K |
| RLAY | Relay Therapeutics | $25.55M | - |
| TCRX | TScan Therapeutics | $21.05M | - |
| ITOS | iTeos Therapeutics | $12.60M | $35.00M |
| CGEM | Cullinan Oncology | - | - |
| GPCR | Structure Therapeutics | - | - |
| XFOR | X4 Pharmaceuticals | - | $560.00K |
| AVRO | AVROBIO | - | - |
| CNSP | CNS Pharmaceuticals | - | - |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| ANNX | Annexon | - | - |
| MDGL | Madrigal Pharmaceuticals | - | $62.17M |
| IMMX | Immix Biopharma | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |